Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 12-Month Low - Here's What Happened

Key Points

• Zealand Pharma A/S shares reached a new 52-week low of $50.25, with previous closing at $52.77 and a trading volume of only 100 shares.
• Despite the drop in stock price, analysts remain optimistic, with Barclays, BNP Paribas, and Wells Fargo assigning a "strong-buy" rating, contributing to a consensus rating of "Strong Buy".
• The company reported a negative EPS of ($0.67) for the last quarter, exceeding estimates, but its revenue was significantly below expectations at $1.14 million against a consensus of $248.61 million.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $50.25 and last traded at $50.25, with a volume of 100 shares changing hands. The stock had previously closed at $52.77.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Wells Fargo & Company upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. Finally, BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. One equities research analyst has rated the stock with a buy rating and five have given a strong buy rating to the company's stock. According to MarketBeat, Zealand Pharma A/S presently has an average rating of "Strong Buy".

Zealand Pharma A/S Stock Down 0.1%

The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. The company has a market cap of $3.56 billion, a price-to-earnings ratio of -20.14 and a beta of 0.71. The stock has a 50-day simple moving average of $60.86 and a 200-day simple moving average of $73.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. As a group, analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.